Similarly, Erlotinib is another FDA-approved drug that acts as an inhibitor of EGFR (86, 87) and has been proven effective in the treatment of NSCLC and metastatic pancreatic cancer when used in combination with gemcitabine (76, 80). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.